Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 69
- Registration Number
- NCT03546855
Apatinib as First -Line Treatment for Advanced Esophagus Cancer
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2018-06-14
- Target Recruit Count
- 50
- Registration Number
- NCT03542422
- Locations
- 🇨🇳
Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2018-05-11
- Target Recruit Count
- 30
- Registration Number
- NCT03521219
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 50
- Registration Number
- NCT03520257
The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2018-04-30
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 40
- Registration Number
- NCT03511703
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT03510416
Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 217
- Registration Number
- NCT03475589
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 67
- Registration Number
- NCT03472365
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Yan Li
- Target Recruit Count
- 30
- Registration Number
- NCT03457467
Apatinib for Advanced Biliary Carcinoma
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 55
- Registration Number
- NCT03427242
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath